Unsere Publikationen

Assessing the immune response to SARS-CoV-2 mRNA vaccines in siponimod-treated patients: a nonrandomized controlled clinical trial (AMA-VACC)

Link
https://doi.org/10.1177/17562864221135305
Tags
Multiple SkleroseMS BehandlungNeuroimmunologie
Jahr
2022
Autoren
Ziemssen T, Groth M, Rauser B, Bopp T.
Verlag
Ther Adv Neurol Disord 2022;15.
Zum Eintrag

S1P receptor modulators and the cardiovascular autonomic nervous system in multiple sclerosis: a narrative review

Link
https://doi.org/10.1177/17562864221133163
Tags
Multiple SkleroseMS BehandlungAutonomes Nervensystem & NeuroendokrinologieHerzratenvariabilität
Jahr
2022
Autoren
Constantinescu V, Haase R, Akgün K, Ziemssen T.
Verlag
Ther Adv Neurol Disord. 2022 Nov 22;15:17562864221133163.
Zum Eintrag

Safety of Fingolimod in Patients with Multiple Sclerosis Switched from Natalizumab: Results from TRANSITION―A 2-Year, Multicenter, Observational, Cohort Study

Link
https://doi.org/10.3390/brainsci12020215
Tags
Multiple SkleroseMS Behandlung
Jahr
2022
Autoren
Butzkueven H, Giacomini PS, Cohan S, Ziemssen T, Sienkiewicz D, Zhang Y, Geissbühler Y, Silva D, Tomic D, Kropshofer H, Trojano M.
Verlag
Brain Sci. 2022 Feb 4;12(2):215.
Zum Eintrag

CONCERTO: A randomized, placebo-controlled trial of oral laquinimod in relapsing-remitting multiple sclerosis

Link
https://doi.org/10.1177/13524585211032803
Tags
Multiple SkleroseMS Behandlung
Jahr
2022
Autoren
Comi G, Dadon Y, Sasson N, Steinerman JR, Knappertz V, Vollmer TL, Boyko A, Vermersch P, Ziemssen T, Montalban X, Lublin FD, Rocca MA, Volkinshtein R, Rubinchick S, Halevy N, Filippi M.
Verlag
Mult Scler. 2022 Apr;28(4):608-619.
Zum Eintrag

Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data

Link
https://doi.org/10.1177/13524585211061335
Tags
Multiple SkleroseMS Behandlung
Jahr
2022
Autoren
Coles AJ, Jones JL, Vermersch P, Traboulsee A, Bass AD, Boster A, Chan A, Comi G, Fernández Ó, Giovannoni G, Kubala Havrdova E, LaGanke C, Montalban X, Oreja-Guevara C, Piehl F, Wiendl H, Ziemssen T.
Verlag
Mult Scler. 2022 Apr;28(5):842-846.
Zum Eintrag

Real-world patient characteristics, treatment patterns and costs in relapsing multiple sclerosis patients treated with glatiramer acetate, dimethyl fumarate or teriflunomide in Germany

Link
https://doi.org/10.2217/nmt-2021-0031
Tags
Multiple SkleroseMS Behandlung
Jahr
2022
Autoren
Ziemssen T, Kurzeja A, Muresan B, Haas JS, Alexander J, Driessen MT.
Verlag
Neurodegenerative Dis Manage 2022;12(2):93-107.
Zum Eintrag

Safety, Adherence and Persistence in a Real-World Cohort of German MS Patients Newly Treated With Ocrelizumab: First Insights From the CONFIDENCE Study

Link
https://doi.org/10.3389/fneur.2022.863105
Tags
Multiple SkleroseMS Behandlung
Jahr
2022
Autoren
Weber MS, Buttmann M, Meuth SG, Dirks P, Muros-Le Rouzic E, Eggebrecht JC, Hieke-Schulz S, Leemhuis J, Ziemssen T.
Verlag
Front Neurol. 2022 May 9;13:863105.
Zum Eintrag

Long-term real-world effectiveness and safety of fingolimod over 5 years in Germany

Link
https://doi.org/10.1007/s00415-021-10931-w
Tags
Multiple SkleroseMS Behandlung
Jahr
2022
Autoren
Ziemssen T, Lang M, Schmidt S, Albrecht H, Klotz L, Haas J, Lassek C, Lang S, Winkelmann VE, Ettle B, Schulze-Topphoff U; PANGAEA study group.
Verlag
J Neurol. 2022 Jun;269(6):3276-3285.
Zum Eintrag
4 5 6 7 8

Publikationen durchsuchen

Publikationen filtern

Filters
Tags
Multiple Sklerose
MS Behandlung
Mobilität
Autonomes Nervensystem & Neuroendokrinologie
Neuroimmunologie
Herzratenvariabilität
Baroreflexsensitivität
Management & Science
eHealth
Gesundheitsökonomie
Andere
Show AllHide
Jahr
-